Sessions
Industry 4.0 Approaches Transforming Cell and Gene Therapy
Changing the Cell Therapy Landscape with In-Vivo Therapies: Is this a Viable Alternative for Point of Care Therapeutics?
Achieving Best Practice in Quality Control and Assurance
Implementing New and Enabling Technologies into Existing Processes for Improved Commercial Outcomes
Analytics, Data and IT Tech Solutions: An Overview of Best Practices and Technology
Delivery Solutions, Improvements and Alternatives for Gene & Cell Therapy
Accelerating the Digitalisation Revolution in Cell and Gene Therapy Development
Viral Vector Development: Safe and Effective Viral Vectors for Therapeutic Success
Industry 4.0 Approaches Transforming Cell and Gene Therapy
SPONSORED BY
11:00 Chairperson’s Opening
Dragan Djordjevic, Associate Director, Cell Therapy Robotics, Data Automation and Machine Learning, Takeda
11:05 Building Better, Faster, Cheaper Enhanced Immunity
- New designs and enhancers
- Advanced x 4 manufacturing
- Advancing access to advanced therapies
Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania; President, International Society for Cell & Gene Therapy
11:20 TESSA Technology: A New Era for AAV Manufacture
- Scalable, plasmid free platform for AAV manufacturing
- TESSA adenoviral systems significantly improve AAV yields
- TESSA-derived AAV is more infectious, more potent, and better packaged than AAV made using plasmids
- Scaling up TESSA-based vectors for GMP manufacturing
Ryan Cawood, Chief Scientific Officer, WuXi Advanced Therapeutics and OXGENE
11:35 What Does Industry 4.0 Mean for Single Use Disposables
- What are the prior revolutions for single use disposables?
- What does compatibility and automation looks like as we evolve into the future?
- Sexton example of forward thinking
Sean Werner, President, Sexton Biotechnologies
11:50 Industry 4.0 Approaches to Data Integration for CGT Manufacturing
Did you know that the majority of CGT manufacturing rely on pen and paper? Autolomous’ platform aims to unlock the power of data to address many of the challenges within CGT manufacturing scale out and up in a safe and compliant manner
- Data risks and challenges with current manufacturing strategies
- Opportunities to do more with less
- AutoloMATE
Kwok Pang, Chief Operating Officer and Co-Founder, Autolomous
12:05 Speaker Q&A and Panel Discussion
Speakers
Bruce Levine
Barbara and Edward Netter Professor in Cancer Gene Therapy; President, International Society for Cell & Gene Therapy
